Akebia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Expands Vafseo Availability Nationwide Across IRC Dialysis Clinics
Akebia Therapeutics, Inc., a biopharmaceutical company focused on improving the lives of those affected by kidney disease, and Innovative Renal Care (IRC) have announced the nationwide availability of Vafseo® (vadadustat) across all IRC dialysis clinics. This collaboration marks a significant step in expanding access to Vafseo, an innovative treatment for anemia due to chronic kidney disease (CKD) in dialysis patients. Implemented through IRC's extensive network of over 230 dialysis centers across 28 states and Washington, D.C., the treatment is now available for patients meeting FDA-approved criteria. This partnership is expected to significantly increase the adoption of Vafseo, which has been accessible to over 55,000 patients and aims to reach more than 275,000 by the end of Q4.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9515883-en) on August 21, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。